Related references
Note: Only part of the references are listed.Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use
Andrew T. Bender et al.
PHARMACOLOGICAL REVIEWS (2006)
Phosphodiesterase-4 as a potential drug target
KYJ Zhang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias
SE Lehnart et al.
CELL (2005)
Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
JE Souness et al.
IMMUNOPHARMACOLOGY (2000)
Phosphodiesterase 4 inhibitors, structurally unrelated to Rolipram, as promising agents for the treatment of asthma and other pathologies
V Dal Piaz et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
